Skip to main content
Top
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Short report

Increased cellular immune responses and CD4+ T-cell proliferation correlate with reduced plasma viral load in SIV challenged recombinant simian varicella virus - simian immunodeficiency virus (rSVV-SIV) vaccinated rhesus macaques

Authors: Bapi Pahar, Wayne L Gray, Kimberly Phelps, Elizabeth S Didier, Eileen deHaro, Preston A Marx, Vicki L Traina-Dorge

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

Background

An effective AIDS vaccine remains one of the highest priorities in HIV-research. Our recent study showed that vaccination of rhesus macaques with recombinant simian varicella virus (rSVV) vector – simian immunodeficiency virus (SIV) envelope and gag genes, induced neutralizing antibodies and cellular immune responses to SIV and also significantly reduced plasma viral loads following intravenous pathogenic challenge with SIVMAC251/CX1.

Findings

The purpose of this study was to define cellular immunological correlates of protection in rSVV-SIV vaccinated and SIV challenged animals. Immunofluorescent staining and multifunctional assessment of SIV-specific T-cell responses were evaluated in both Experimental and Control vaccinated animal groups. Significant increases in the proliferating CD4+ T-cell population and polyfunctional T-cell responses were observed in all Experimental-vaccinated animals compared with the Control-vaccinated animals.

Conclusions

Increased CD4+ T-cell proliferation was significantly and inversely correlated with plasma viral load. Increased SIV-specific polyfunctional cytokine responses and increased proliferation of CD4+ T-cell may be crucial to control plasma viral loads in vaccinated and SIVMAC251/CX1 challenged macaques.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pahar B, Lackner AA, Piatak M Jr, Lifson JD, Wang X, Das A, Ling B, Montefiori DC, Veazey RS: Control of viremia and maintenance of intestinal CD4(+) memory T-cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Virology 2009, 387: 273-284.PubMedPubMedCentralCrossRef Pahar B, Lackner AA, Piatak M Jr, Lifson JD, Wang X, Das A, Ling B, Montefiori DC, Veazey RS: Control of viremia and maintenance of intestinal CD4(+) memory T-cells in SHIV(162P3) infected macaques after pathogenic SIV(MAC251) challenge. Virology 2009, 387: 273-284.PubMedPubMedCentralCrossRef
2.
go back to reference Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC: HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7: 19-23.PubMedCrossRef Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC: HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7: 19-23.PubMedCrossRef
3.
go back to reference Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, Unger RE, Ramos RA, Kiyono H, McGhee JR, et al.: Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol 1992, 21: 99-107.PubMed Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, Unger RE, Ramos RA, Kiyono H, McGhee JR, et al.: Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol 1992, 21: 99-107.PubMed
4.
go back to reference Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361: 2209-2220.PubMedCrossRef Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361: 2209-2220.PubMedCrossRef
5.
go back to reference Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, Sanmiguel A, Seaman MS, Ferrari G, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482: 89-93.PubMedPubMedCentralCrossRef Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, Sanmiguel A, Seaman MS, Ferrari G, et al.: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012, 482: 89-93.PubMedPubMedCentralCrossRef
6.
go back to reference Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473: 523-527.PubMedPubMedCentralCrossRef Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473: 523-527.PubMedPubMedCentralCrossRef
7.
go back to reference Arvin AM, Mallory S, Moffat JF: Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 1999, 3: 193-200.PubMedCrossRef Arvin AM, Mallory S, Moffat JF: Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol 1999, 3: 193-200.PubMedCrossRef
8.
go back to reference Gray WL: Simian varicella: a model for human varicella-zoster virus infections. Rev Med Virol 2004, 14: 363-381.PubMedCrossRef Gray WL: Simian varicella: a model for human varicella-zoster virus infections. Rev Med Virol 2004, 14: 363-381.PubMedCrossRef
10.
go back to reference Traina-Dorge V, Pahar B, Marx P, Kissinger P, Montefiori D, Ou Y, Gray WL: Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Vaccine 2010, 28: 6483-6490.PubMedPubMedCentralCrossRef Traina-Dorge V, Pahar B, Marx P, Kissinger P, Montefiori D, Ou Y, Gray WL: Recombinant varicella vaccines induce neutralizing antibodies and cellular immune responses to SIV and reduce viral loads in immunized rhesus macaques. Vaccine 2010, 28: 6483-6490.PubMedPubMedCentralCrossRef
11.
go back to reference Ou Y, Traina-Dorge V, Davis KA, Gray WL: Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 2007, 364: 291-300.PubMedPubMedCentralCrossRef Ou Y, Traina-Dorge V, Davis KA, Gray WL: Recombinant simian varicella viruses induce immune responses to simian immunodeficiency virus (SIV) antigens in immunized vervet monkeys. Virology 2007, 364: 291-300.PubMedPubMedCentralCrossRef
12.
go back to reference Pahar B, Cantu MA, Zhao W, Kuroda MJ, Veazey RS, Montefiori DC, Clements JD, Aye PP, Lackner AA, Lovgren-Bengtsson K, Sestak K: Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. Vaccine 2006, 24: 6839-6849.PubMedCrossRef Pahar B, Cantu MA, Zhao W, Kuroda MJ, Veazey RS, Montefiori DC, Clements JD, Aye PP, Lackner AA, Lovgren-Bengtsson K, Sestak K: Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. Vaccine 2006, 24: 6839-6849.PubMedCrossRef
13.
go back to reference Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, Miedema F, Hamann D: T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95: 249-255.PubMed Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, Miedema F, Hamann D: T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95: 249-255.PubMed
14.
go back to reference Kaur A, Hale CL, Ramanujan S, Jain RK, Johnson RP: Differential dynamics of CD4(+) and CD8(+) T-lymphocyte proliferation and activation in acute simian immunodeficiency virus infection. J Virol 2000, 74: 8413-8424.PubMedPubMedCentralCrossRef Kaur A, Hale CL, Ramanujan S, Jain RK, Johnson RP: Differential dynamics of CD4(+) and CD8(+) T-lymphocyte proliferation and activation in acute simian immunodeficiency virus infection. J Virol 2000, 74: 8413-8424.PubMedPubMedCentralCrossRef
15.
go back to reference Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179: 859-870.PubMedCrossRef Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, Shih R, Lewis J, Wiley DJ, Phair JP, et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999, 179: 859-870.PubMedCrossRef
16.
go back to reference Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS: Virus-specific T-cell responses in macaques acutely infected with SHIV(sf162p3). Virology 2007, 363: 36-47.PubMedPubMedCentralCrossRef Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS: Virus-specific T-cell responses in macaques acutely infected with SHIV(sf162p3). Virology 2007, 363: 36-47.PubMedPubMedCentralCrossRef
17.
go back to reference Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, et al.: HIV-1-specific interleukin-21+ CD4+ T-cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T-cell function. J Virol 2011, 85: 733-741.PubMedPubMedCentralCrossRef Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J, Lian J, Muller MI, et al.: HIV-1-specific interleukin-21+ CD4+ T-cell responses contribute to durable viral control through the modulation of HIV-specific CD8+ T-cell function. J Virol 2011, 85: 733-741.PubMedPubMedCentralCrossRef
18.
go back to reference Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, Rosenberg ES: Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T-cells. J Virol 2004, 78: 8844-8851.PubMedPubMedCentralCrossRef Norris PJ, Moffett HF, Yang OO, Kaufmann DE, Clark MJ, Addo MM, Rosenberg ES: Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T-cells. J Virol 2004, 78: 8844-8851.PubMedPubMedCentralCrossRef
20.
go back to reference Harari A, Petitpierre S, Vallelian F, Pantaleo G: Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004, 103: 966-972.PubMedCrossRef Harari A, Petitpierre S, Vallelian F, Pantaleo G: Skewed representation of functionally distinct populations of virus-specific CD4 T-cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004, 103: 966-972.PubMedCrossRef
21.
go back to reference Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 1997, 278: 1447-1450.PubMedCrossRef Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viremia. Science 1997, 278: 1447-1450.PubMedCrossRef
22.
go back to reference Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, et al.: HIV preferentially infects HIV-specific CD4+ T-cells. Nature 2002, 417: 95-98.PubMedCrossRef Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, et al.: HIV preferentially infects HIV-specific CD4+ T-cells. Nature 2002, 417: 95-98.PubMedCrossRef
Metadata
Title
Increased cellular immune responses and CD4+ T-cell proliferation correlate with reduced plasma viral load in SIV challenged recombinant simian varicella virus - simian immunodeficiency virus (rSVV-SIV) vaccinated rhesus macaques
Authors
Bapi Pahar
Wayne L Gray
Kimberly Phelps
Elizabeth S Didier
Eileen deHaro
Preston A Marx
Vicki L Traina-Dorge
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-160

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.